<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216748</url>
  </required_header>
  <id_info>
    <org_study_id>20070583</org_study_id>
    <secondary_id>R01HL060644</secondary_id>
    <nct_id>NCT01216748</nct_id>
  </id_info>
  <brief_title>Clinical Evidence of pH Dependent ß2 Adrenergic Transport Mechanisms in the Airway</brief_title>
  <official_title>Clinical Evidence of pH Dependent ß2 Adrenergic Transport Mechanisms in the Airway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine if airway pH has an effect on albuterol-induced
      vasodilation in the airway. Methods: Ten healthy volunteers performed the following
      respiratory maneuvers: quiet breathing, hypocapnic hyperventilation, hypercapnic
      hyperventilation, and eucapnic hyperventilation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The lungs provide a unique absorptive surface for drug delivery. Many inhaled drugs are
      rapidly absorbed into the airway because of their lipophilic chemical characteristics.
      However, the majority of the currently used β2-adrenergic bronchodilators cannot freely
      diffuse across the epithelial cell membrane because of their transient or permanent positive
      charge at physiological pH. Inhaled albuterol, a β2-adrenergic agonist used widely for the
      treatment of obstructive airway disease, is charged positively in neutral or acidic
      conditions and thus requires active transport across the airway epithelium. Previous studies
      in the lab have shown that albuterol uptake into airway epithelia occurs via a pH sensitive
      cation transporter (OCTN2). The vasodilator response to an inhaled β2-adrenergic agonist
      could be an expression of epithelial cation transport. The investigators propose that the
      magnitude and duration of vasodilation in the airway caused by an inhaled hydrophilic
      β2-adrenergic agonist such as albuterol may be altered by changes in airway pH. The purpose
      of this protocol is to determine the effect of ASL pH on the response of Qaw to inhaled
      albuterol by manipulating airway pH through ventilatory maneuvers in health subjects:
      hyperventilation to raise pH and ventilation with CO2 bleed-in to lower pH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Airway Blood Flow After 180μg Albuterol by Inhalation (ΔQaw) vs Baseline</measure>
    <time_frame>15 minutes after albuterol inhalation</time_frame>
    <description>Effect of airway pH on albuterol responsiveness as reflected by the change in airway blood flow after 180μg albuterol by inhalation (ΔQaw) vs baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled Breath Condensate (EBC) pH Variation</measure>
    <time_frame>10 minutes after each respiratory manouver.</time_frame>
    <description>EBC samples were collected at each respiratory maneuver by directing the subject's exhaled breath into a pre-cooled (-10C) tube for 10 min.
pH was measured immediately after collection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>health life-time non smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>health lifetime non-smokers will be challenged with 4 respiratory maneuvers:quiet breathing, hypocapnic hyperventilation, hypercapnic hyperventilation, and eucapnic hyperventilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quiet breathing</intervention_name>
    <description>Subjects were instructed to breath normally at room air.</description>
    <arm_group_label>health life-time non smokers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypocapnic Hyperventilation</intervention_name>
    <description>hypocapnic hyperventilation, the subjects were instructed to breathe fast and deep until their end-tidal pCO2 fell to 30 mmHg, corresponding to a systemic pH increase of about 0.1 pH units.</description>
    <arm_group_label>health life-time non smokers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypercapnic Hyperventilation</intervention_name>
    <description>For hypercapnic hyperventilation, a modification of a previously described procedure (15). While monitoring SaO2 using pulse oximetry and end-tidal CO2 by mass-spectrometry on a breath by breath basis, CO2 was bled into the inspired air to achieve an end-tidal pCO2 of at least 55 mmHg</description>
    <arm_group_label>health life-time non smokers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>eucapnic hyperventilation</intervention_name>
    <description>For eucapnic hyperventilation, the subjects were instructed to increase their ventilation to the highest level of ventilation recorded in the previous two hyperventilation maneuvers, while CO2 was bled into the inspired air to maintain end-tidal pCO2 at 40 mmHg.</description>
    <arm_group_label>health life-time non smokers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lifetime non-smokers

          -  FEV1 &gt; 80% predicted value and FEV1/FVC &gt; 0.75

        Exclusion Criteria:

          -  Cardiovascular disease or use of cardiovascular or vasoactive drugs;

          -  Lung disease or use of airway drugs (i.e. inhaled corticosteroids, β adrenergic
             agonists);

          -  Respiratory infection during the 4 weeks preceding the study

          -  Use of systemic glucocorticoids within 4 weeks of the study

          -  Pregnant or nursing females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Salathe</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Human Research Laboratory, University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vaughan J, Ngamtrakulpanit L, Pajewski TN, Turner R, Nguyen TA, Smith A, Urban P, Hom S, Gaston B, Hunt J. Exhaled breath condensate pH is a robust and reproducible assay of airway acidity. Eur Respir J. 2003 Dec;22(6):889-94.</citation>
    <PMID>14680074</PMID>
  </reference>
  <reference>
    <citation>Paget-Brown AO, Ngamtrakulpanit L, Smith A, Bunyan D, Hom S, Nguyen A, Hunt JF. Normative data for pH of exhaled breath condensate. Chest. 2006 Feb;129(2):426-30.</citation>
    <PMID>16478862</PMID>
  </reference>
  <reference>
    <citation>Horvath G, Schmid N, Fragoso MA, Schmid A, Conner GE, Salathe M, Wanner A. Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway. Am J Respir Cell Mol Biol. 2007 Jan;36(1):53-60. Epub 2006 Aug 17.</citation>
    <PMID>16917073</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <results_first_submitted>September 2, 2014</results_first_submitted>
  <results_first_submitted_qc>December 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2014</results_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Matthias Salathe</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>airway blood flow</keyword>
  <keyword>albuterol</keyword>
  <keyword>acidosis</keyword>
  <keyword>alkalosis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>healthy lifetime non smokers were challenged with 4 respiratory manouvers: quiet breathing, hypocapnic hyperventilation, hypercapnic hyperventilation, and eucapnic hyperventilation in random order.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Quiet Breathing</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Hypocapnic Hyperventilation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Hypercapnic Hyperventilation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eucapnic Hyperventilation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Controls</title>
          <description>health-lifetime non-smokers were enrolled</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="23" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Airway Blood Flow After 180μg Albuterol by Inhalation (ΔQaw) vs Baseline</title>
        <description>Effect of airway pH on albuterol responsiveness as reflected by the change in airway blood flow after 180μg albuterol by inhalation (ΔQaw) vs baseline.</description>
        <time_frame>15 minutes after albuterol inhalation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Health Controls</title>
            <description>Health lifetime non smokers were recruited.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Airway Blood Flow After 180μg Albuterol by Inhalation (ΔQaw) vs Baseline</title>
          <description>Effect of airway pH on albuterol responsiveness as reflected by the change in airway blood flow after 180μg albuterol by inhalation (ΔQaw) vs baseline.</description>
          <units>changes from baseline in μl.min-1.ml-1</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>quiet breathing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eucapnic hyperventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypocapnic hyperventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypercapnic hyperventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exhaled Breath Condensate (EBC) pH Variation</title>
        <description>EBC samples were collected at each respiratory maneuver by directing the subject's exhaled breath into a pre-cooled (-10C) tube for 10 min.
pH was measured immediately after collection.</description>
        <time_frame>10 minutes after each respiratory manouver.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Health Controls</title>
            <description>Health lifetime non smokers were recruited.</description>
          </group>
        </group_list>
        <measure>
          <title>Exhaled Breath Condensate (EBC) pH Variation</title>
          <description>EBC samples were collected at each respiratory maneuver by directing the subject's exhaled breath into a pre-cooled (-10C) tube for 10 min.
pH was measured immediately after collection.</description>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>quiet breathing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypocapnic hyperventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.31" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypercapnic hyperventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.59" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eucapnic hyperventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Health Controls</title>
          <description>Health lifetime non smokers were recruited.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthias Salathe, MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>(305)243-2568</phone>
      <email>msalathe@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

